Analyst Tiago Fauth from Wells Fargo maintained a Buy rating on PTC Therapeutics (PTCT – Research Report) and keeping the price target at $74.00.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Tiago Fauth has given his Buy rating due to a combination of factors related to PTC Therapeutics’ recent developments and market potential. The European Commission’s marketing authorization for Sephience, covering all ages and disease severities, is a significant milestone, with the launch expected in Germany soon. This approval extends to all EU member states and additional countries, indicating a broad market reach.
Moreover, survey results suggest a high willingness among prescribers to adopt Sephience, with notable conversion rates from existing therapies and potential expansion into new patient segments. Fauth anticipates that peak sales could exceed current consensus estimates, driven by a conservative pricing model and potential international revenues. Additionally, the ongoing review of sepiapterin’s approval in the US and other countries, along with supportive trial designs for related treatments, further strengthens the investment case.
Based on the recent corporate insider activity of 43 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of PTCT in relation to earlier this year.